Boky Jeanne Tuasikal

Boky Jeanne Tuasikal

Auto-generated profile, based on publicly available information

Boky Jeanne Tuasikal

Research Organization for Nuclear Energy Research Center for Radiation Process Technology National Research and Innovation Agency (BRIN) Building 71 Kawasan Puspiptek Setu Tangerang Selatan 15310 Banten Indonesia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
RMRicha Mardianingrum
Richa Mardianingrum
SSSusanti Susanti
Susanti Susanti
Muchtaridi MuchtaridiMuchtaridi Muchtaridi
Muchtaridi Muchtaridi
RRRuswanto Ruswanto
Ruswanto Ruswanto
Ine SuharyaniIne Suharyani
Ine Suharyani
BTBoky J. Tuasikal
Boky J. Tuasikal
Context: The development of radiopharmaceuticals derived from natural compounds has been extensively studied, particularly for cancer treatment. α-Mangostin is a molecule claimed to be toxic to cancer cells, and its derivative, an organometallic compound, has been synthesized successfully, namely bis-(α-mangostin)-cobalt(II) or AM-Co. The AM-Co structure shows promise as a radiopharmaceutical candidate, especially when labelled with radioactive iodine. Aims: To optimise the radiolabelling conditions of AM-Co with iodine-131 and assess its internalization profile in breast cancer cell lines, as well as biodistribution and pharmacokinetic profile using in vivo approaches. Methods: The radiolabelling of [131I]I-AM-Co was carried out by electrophilic aromatic substitution, with CATas the oxidising agent at low temperatures for synthesis. Internalization studies of [131I]I-AM-Co were conducted in MCF-7 cell lines. Additionally, the biodistribution and pharmacokinetic profiles were assessed by administering 0.37–1.11 MBq of [131I]I-AM-Co (i.v. route) in normal mice and rats. Results: The [131I]I-AM-Co was successfully synthesized with radiopharmaceutical purity of 99.12 ± 0.18% and internalized into MCF-7 cell lines greater than 46% after one hour of incubation. In addition, [131I]I-AM-Co demonstrates 11 times slower diffusion from blood into organs compared with iodine -131, with t½ α was 0.33 ± 0.17 hour. Interestingly, based on AUC data, it reveals that systemic exposure of [131I]I-AM-Co exhibits increasing five times than iodine-131. However, the highest accumulation of [131I]I-AM-Co was still found in the thyroid gland. Conclusions: The [131I]I-AM-Co can be synthesized, achieving a radiochemical purity of over 90%. In addition, the [131I]I-AM-Co compound greatly enhances cellular uptake and plasma concentration compared to iodine-131, which exhibits rapid clearance.

16 January 2025 in Pharmacia
Verified
Journal Article
Open access
PDF file
DPDian Pribadi Perkasa
Dian Pribadi Perkasa
IKIin Kurnia
Iin Kurnia
TFTaufik Muhammad Fakih
Taufik Muhammad Fakih
TKTeja Kisnanto
Teja Kisnanto
DRDwi Ramadhani
Dwi Ramadhani
MSMukh Syaifudin
Mukh Syaifudin
The radioprotective potential of Sitahe (Leuconotis eugenifolia) phytochemicals in cancer radiotherapy remains largely unexplored. In this study, in silico docking simulations were conducted to systematically assess the ability of key phytochemicals from Sitahe to modulate p53 activity, a critical gene in DNA repair and cancer therapy. SwissADME analysis revealed favorable physicochemical properties for compounds such as baurenol, alpha amyrin, and beta amyrin, although high lipophilicity may pose challenges for bioavailability. Molecular docking studies identified strong binding affinities between these compounds and the p53 DNA binding domain, with baurenol demonstrating the highest binding affinity at −6.75 kcal/mol, which is better compared to rhazinilam (−4.55 kcal/mol), leuconolam (−4.36 kcal/mol), leuconoxine (−4.26 kcal/mol), and dehydroleuconoxine (−4.76 kcal/mol). Hydrogen bonding with key residues such as Thr123 further enhanced the stability of these complexes. The low inhibition constants (Ki) suggest significant inhibitory potential, particularly for baurenol (11.31 μM). To evaluate the stability and reliability of these interactions, molecular dynamics (MD) simulations were performed over a duration of 500 ns. The results demonstrated that the selected compounds maintained stable molecular dynamics profiles, showing consistent interactions with the target protein throughout the simulation period. Among the compounds tested, baurenol exhibited the best performance with a MM/PBSA binding energy of −68.568 kJ/mol, which is better than rhazinilam (−63.538 kJ/mol). These findings suggest that baurenol, along with other Sitahe phytochemicals, could serve as dual-function agents, offering protection to healthy tissues from radiation-induced damage while targeting cancer cells through p53 modulation. Although these in silico and MD results are promising, further validation through in vitro and in vivo studies is essential to confirm their therapeutic potential and optimize their pharmacokinetic properties. This study positions Sitahe phytochemicals, particularly baurenol, as promising candidates for the development of novel radioprotective agents in cancer treatment.